| Kathleen Veit |
Kathleen Veit is currently the Senior VP-Global Compliance & Ethics Officer at Teva Pharmaceutical Industries Ltd. She graduated from Seton Hall University with a graduate degree and from West Chester University of Pennsylvania with an undergraduate degree. |
| Eric Drapé |
Eric Drapé is currently the Director at Laboratoire Français du Fractionnement et des Biotechnologies and Ipsen Manufacturing Ireland Ltd. He is also the Executive Vice President-Global Operations at Teva Pharmaceutical Industries Ltd. since 2019. Previously, he served as the Chairman at Beaufour Ipsen Industrie SAS and as a Director at Ipsen Biopharm Ltd. He was also the Executive Vice President-Manufacturing & Supply at Ipsen SA from 2009 to 2010. Additionally, he held the position of Senior Vice President-Diabetes Finished Products at Novo Nordisk SAS. From 2007 to 2013, he was the Executive Vice President-Technical Operations at Ipsen Pharma SAS. Dr. Drapé obtained a doctorate degree from Université de Paris XI Paris Sud in 1986 and an MBA from Scandinavian International Management Institute in 1999. |
| David R. McAvoy |
David R. McAvoy is currently the Director at Villages of Indiana and the Chief Legal Officer & Executive Vice President at Teva Pharmaceutical Industries Ltd. He previously worked as the General Counsel-Lilly Emerging Markets at Eli Lilly & Co., Chief Compliance Officer & General Counsel at Vical, Inc., Chief Compliance Officer & General Counsel at Brickell Subsidiary, Inc., Chief Compliance Officer & General Counsel at Endocyte, Inc., and Chief Compliance Officer & General Counsel at Fresh Tracks Therapeutics, Inc. Mr. McAvoy completed his undergraduate degree at the University of Notre Dame and his graduate degree at Indiana University. |
| David M. Stark |
Presently, David M. Stark holds the position of Chief Legal Officer & Executive Vice President at Teva Pharmaceutical Industries Ltd. Mr. Stark is also Member of Cold Spring Harbor Laboratory, Inc.
In the past he was Associate-Litigation Department at Willkie Farr & Gallagher LLP, Associate-Litigation Department at Chadbourne & Parke LLP, Associate-Litigation Department at Haight Gardner, Poor & Havens and Senior Director, Vice President & General Counsel at Teva North America.
He received a graduate degree from New York University School of Law and an undergraduate degree from Northeastern University. |
| Mark Sabag |
Mark Sabag is currently a member of the Board of Directors at Sanara Ventures Ltd. He also holds the position of EVP-International Markets Commercial Division at Teva Pharmaceutical Industries Ltd. Mr. Sabag previously served as an Independent Director at PCB Technologies Ltd. and as the Head-Senior Global Human Resources at Intel Corp. He obtained his undergraduate and graduate degrees from the University of Haifa in 1995. |
| Nir Baron |
Nir Baron is currently the Chief Internal Auditor & Senior Vice President at Teva Pharmaceutical Industries Ltd. He is also a Member of the Israel Bar Association. Previously, he worked as the Director-Investigations & Intelligence at the Israel Securities Authority from 2007 to 2012. Mr. Baron holds a graduate degree from Tel-Aviv University, an undergraduate degree from Tel-Aviv University, and another graduate degree from Ben-Gurion University of the Negev. |
| Eli Kalif |
Eli Kalif is currently the Chief Financial Officer & Executive Vice President at Teva Pharmaceutical Industries Ltd. He is also an Advisor at New Era Capital Partners. Previously, he worked at Flex Ltd. for 18 years, where he held the position of Senior Vice President-Finance from 2010 to 2019. Mr. Kalif is a graduate of Stanford University and holds an undergraduate degree from The College of Management Academic Studies. |
| Sol J. Barer |
Sol J. Barer is the founder of Celgene SAS (1986), Barer & Son Capital LLC (2017), Celgene Corp. (1986), and Centrexion Therapeutics Corp. (2013). He is currently the Chairman at Teva Pharmaceutical Industries Ltd. (since 2015), NexImmune, Inc. (since 2019), Medgenics Medical (Israel) Ltd., Hackensack Meridian School of Medicine, Semorex, Inc., BioNJ, Inc. (since 2010), 3D Bio Holdings, Inc. (since 2019), Zephyr AI, Inc., Brooklyn College Foundation, Liberty Science Center, The Tourette Association of America, SJBarer Consulting LLC, and Israel Biotech Fund. He has held former positions as Chairman at Edge Therapeutics, Inc. (2011-2019), the University of Medicine & Dentistry of New Jersey, and Aevi Genomic Medicine, Inc. (2012-2020). He was also Chairman at Avalo Therapeutics, Inc. and RestorGenex Corp. (2013-2016), and served as an Independent Director at Amicus Therapeutics, Inc. (2009-2017) and Aegerion Pharmaceuticals, Inc. (2011-2016). Additionally, he has served as a Director at Cornerstone Pharmaceuticals, Inc., Nobex Corp., and Pharmaceutical Research & Manufacturers of America. He is currently the Lead Independent Director at ContraFect Corp. (since 2011) and has served as an Independent Non-Executive Director at InspireMD, Inc. (2011-2017). He has also held positions as a Trustee at Rutgers State University of New Jersey and the New Jersey Commission on Science & Technology. Dr. Barer received his undergraduate degree from Brooklyn College in 1968 and his doctorate degree from Rutgers State University of New Jersey in 1974. |
| Eric A. Hughes |
Eric A. Hughes is currently the Chief Medical Officer and Executive VP-Global R&D at Teva Pharmaceutical Industries Ltd. He holds a doctorate degree from Yale School of Medicine. |
| Amir Weiss |
Amir Weiss is currently the Chief Accounting Officer & Senior Vice President at Teva Pharmaceutical Industries Ltd. Prior to his current position, he worked as the Controller at RADCOM Ltd. from 2008 to 2012 and at Oblicore, Inc. from 2006 to 2008. Mr. Weiss completed his undergraduate, graduate, and MBA degrees at Bar-Ilan University. |
| John Nason |
John Nason is President-Biologics Operations at Teva Pharmaceutical Industries Ltd. |
| Richard Francis |
Richard Francis is currently the President, Chief Executive Officer & Director at Teva Pharmaceutical Industries Ltd. He is also an Independent Director at Mettler-Toledo International, Inc., a Director at Mettler-Toledo (Schweiz) GmbH, and a Director at Purespring Therapeutics Ltd. Previously, he served as the Chief Executive Officer & Division Head at Sandoz International GmbH from 2014 to 2019. He was also the Chief Executive Officer at Forcefield Therapeutics Ltd. and the Senior Vice President at Biogen, Inc. from 2006 to 2014. Mr. Francis obtained his undergraduate degree from Manchester Metropolitan University. |
| Ronit Satchi-Fainaro |
Ronit Satchi-Fainaro is currently an Independent Director at Teva Pharmaceutical Industries Ltd. and the Director of the Biology Research Center at Tel-Aviv University. She is also a Director at The Israel Cancer Association, the Blavatnik Center For Drug Discovery, and Vall D’Hebron University Hospital. Additionally, she serves as an Advisory Board Member at The Energy Federation, Inc. and an Advisor at Van Leer Xenia Ventures. She is a Member of 8400 The Health Network. Previously, she served as the President of The Controlled Release Society from 2010 to 2014. Dr. Satchi-Fainaro holds a doctorate degree from the University of London and an undergraduate degree from The Hebrew University of Jerusalem. |
| Varda Shalev |
Varda Shalev is the founder of Alike Ltd. (founded in 2020) and holds the title of Chief Medical Officer. Dr. Shalev's current job(s) include being an Independent Director at Teva Pharmaceutical Industries Ltd. since 2023. , a Non-Executive Director at BATM Advanced Communications Ltd. since 2018, a Director at Israel Advanced Technology Industries, a Director at Novolog (Pharm UP 1966) Ltd. since 2022, a Director at Mkm Nstitute For Health Research & Innovation, a Professor-Public Health at Tel-Aviv University since 2019, a Chief Medical Officer at Alike, Inc. since 2020, and a Managing Partner at Team8 Labs Ltd. since 2022. Dr. Shalev's former job(s) include being an Independent Director at Pluri, Inc. from 2021 to 2023 and the Head-Primary Care Division at Maccabi Healthcare Services from 2013 to 2015. Dr. Shalev's education history includes a graduate degree from Clark University and a doctorate degree from Ben-Gurion University of the Negev. |
| Tal Zaks |
Tal Zaks is currently an Independent Director at Teva Pharmaceutical Industries Ltd. He is also an Associate Professor-Medicine at the University of Pennsylvania and at Tufts Medical Center, Inc. Dr. Zaks is a Partner at OrbiMed Advisors Private Equity and a Member & Strategic Advisory Board at Deep Genomics, Inc. Previously, Dr. Zaks worked as a Director-Clinical Development & Translational at GlaxoSmithKline (New Jersey). He was an Independent Non-Executive Director at Adaptimmune Therapeutics Plc from 2016 to 2023. Dr. Zaks served as the Vice President-Clinical Research at Cephalon, Inc. from 2008 to 2010. He was also the Senior Vice President & Head-Global Oncology at Sanofi, Inc. from 2010 to 2015. Dr. Zaks held the position of Chief Medical Officer at Moderna, Inc. from 2015 to 2021. Dr. Zaks holds a doctorate degree from Ben-Gurion University of the Negev, which he received in 2000. He also has an undergraduate degree from the University of Pennsylvania Medical Center, which he obtained in 2004. |
| Janet S. Vergis |
Janet S. Vergis is the founder of Nulatis Therapeutics, Inc. She currently holds the following positions: Independent Director at Church & Dwight Co., Inc. since 2014, Independent Director at Teva Pharmaceutical Industries Ltd. since 2020, Director at IMPAX Corp since 2015, Director at National Association of Corporate Directors, Independent Director at Dentsply Sirona, Inc. since 2019, Director at Dentsply Sirona France SAS since 2021, and Director at SGS SA since 2021. Ms. Vergis has previously worked as the Chief Executive Officer & Director at OraPharma, Inc. from 2010 to 2012, Director at AMAG Pharma USA, Inc. from 2013 to 2014, Director at MedDay Pharmaceuticals SAS from 2016 to 2021, Independent Director at Amneal Intermediate, Inc. from 2015 to 2019, Executive-in-Residence at Warburg Pincus LLC from 2013 to 2014, President at Janssen Pharmaceuticals, Inc. from 2004 to 2009, President at Ortho-mcneil Neurologics, Inc. from 2004 to 2009, and President at McNeil Pediatrics from 2004 to 2009. Ms. Vergis obtained her undergraduate and graduate degrees from The Pennsylvania State University in 1987 and 1988, respectively. |
| Roberto Agostino Mignone |
Roberto Agostino Mignone is the founder of Bridger Management LLC, which was founded in 2000, where he holds the title of Manager. He was also the founder of Blue Ridge Capital LLC, which was founded in 1996, where he held the title of Partner from 1996 to 2000. Currently, Mr. Mignone holds the position of Vice Chairman at NYU Langone Hospitals and Co-Vice Chairman at NYU Langone Health. He is also an Independent Director at Teva Pharmaceutical Industries Ltd. since 2017 and at Avanti Acquisition Corp. since 2020. In terms of education, Mr. Mignone obtained an MBA from Harvard Business School in 1996. He also completed his undergraduate studies at Harvard College. |
| Shah Abbas Hussain |
Shah Abbas Hussain currently works at Mallinckrodt Plc, as Independent Director from 2024 and GlaxoSmithKline South Africa (Pty) Ltd., as President-Emerging Markets Asia Pacific from 2009. Mr. Hussain also formerly worked at Vifor Pharma AG, as Chief Executive Officer, Vifor Pharma, Inc., as Chief Executive Officer, Teva Pharmaceutical Industries Ltd., as Independent Director from 2020 to 2021, CSL Ltd., as Independent Non-Executive Director from 2018 to 2021, Cochlear Ltd., as Independent Non-Executive Director from 2018 to 2021, Aspen Pharmacare Holdings Ltd., as Non-Executive Director from 2009 to 2015, Eli Lilly Ranbaxy Ltd., as Director-Sales & Marketing, ViiV Healthcare Ltd., as Director from 2009 to 2017, Duke-NUS Graduate Medical School Singapore, as Director, Lilly Ilaç Ticaret Ltd. Sti., as Managing Director, TargTex SA, as Director, Immunocore Holdings Plc, as Non-Executive Director from 2017 to 2020, Eli Lilly & Co., as Associate-Business Development, Genelabs Technologies, Inc., as President-Emerging Markets & Asia Pacific, GSK Plc, as Global President-Pharmaceuticals & Vaccines from 2013 to 2017, Eli Lilly & Co. Ltd., as President-Europe Operations from 2006 to 2008, Lilly Deutschland GmbH, as General Manager, Eli Lilly Australia Pty Ltd., as Manager-District Sales, Lilly Pharma Holding GmbH, as General Manager, and CBC Group (Singapore) Pte. Ltd., as Senior Partner. Mr. Hussain received his undergraduate degree from Loughborough University. |
| Rosemary A. Crane |
Rosemary A. Crane currently works at Teva Pharmaceutical Industries Ltd., as Independent Director from 2015, HMH Hospitals Corp, Inc., as Director-Discovery & Innovation, Catalent Pharma Solutions, Inc., as Director from 2018, Tarsus Pharmaceuticals, Inc., as Independent Director from 2021, Certara, Inc., as Independent Director from 2022, Hackensack Meridian Health Center For Discovery & Innovation, as Director, and The State University of New York, as Member-Foundation Board. Ms. Crane also formerly worked at Epocrates LLC, as President, Chief Executive Officer & Director in 2011, STRATA Skin Sciences, Inc., as President, Chief Executive Officer & Director in 2014, Epocrates, Inc. (Research), as President & Chief Executive Officer in 2011, MELA Sciences Inc., as President & Chief Executive Officer from 2013 to 2014, Johnson & Johnson, as Group Chairman-OTC & Nutritional Group from 2006 to 2008, Zealand Pharma A, as Vice Chairman from 2015 to 2019, Cipher Pharmaceuticals, Inc., as Director in 2016, Targanta Therapeutics Corp., as Director from 2008 to 2009, Edge Therapeutics, Inc., as Independent Director from 2017 to 2019, Unilife Corp., as Independent Director from 2016 to 2017, Unilife Medical Solutions, Inc., as Director, Catalent, Inc., as Independent Director from 2018 to 2024, Bristol Myers Squibb Co., as President-US Primary Care Division from 2000 to 2002, and Apple Tree venture Managemnet Llc, as Partner in 2013. Ms. Crane received her undergraduate degree in 1981 from State University of New York College at Oswego and Masters Business Admin degree in 1986 from Kent State University (Ohio). |
| Amir Elstein |
Amir Elstein is currently the Chairman at Tower Semiconductor Ltd., Chairman at Israel Democracy Institute, Chairman at TowerJazz Japan Ltd., Independent Director at Teva Pharmaceutical Industries Ltd., and Director at The Israel National Nanotechnology Initiative. He previously served as Chairman at Israel Corp. Ltd. from 2010 to 2013, Chairman-Governors Board at Jerusalem College of Engineering from 2009 to 2018, and held director positions at ZIM Integrated Shipping Services Ltd., Better Place, Inc., Qoros Automotive Co., Ltd., and Intel Electronics Ltd. Mr. Elstein received his undergraduate and graduate degrees from The Hebrew University of Jerusalem in 1980 and 1982 respectively. |
| Perry D. Nisen |
Perry D. Nisen is currently the Chief Executive Officer & Director at Quanta Therapeutics, Inc., an Independent Director at Teva Pharmaceutical Industries Ltd., a Director at California Biomedical Innovation Alliance, and an Executive Partner & Private Equity at Sofinnova Investments, Inc. Previously, he served as the Chief Executive Officer & Trustee at Sanford Burnham Prebys Medical Discovery Institute, an Independent Director at Mirna Therapeutics, Inc., and a Senior Vice President-Science & Innovation at GlaxoSmithKline LLC. He was also a VP-Cancer Research & Oncology Development at Abbott Laboratories. Dr. Nisen's education includes an undergraduate degree from Stanford University and graduate and doctorate degrees from Albert Einstein College of Medicine, Inc. |
| Gerald M. Lieberman |
Gerald M. Lieberman is currently the Independent Chairman at Entera Bio Ltd. and the Chairman at Dosentrx Ltd. He is also an Independent Director at Teva Pharmaceutical Industries Ltd., a Board of Director at AllianceBernstein (Luxembourg) SARL, a Director at AllianceBernstein Corp., and a Special Advisor at Reverence Capital Partners LLC. In the past, Mr. Lieberman served as the Chief Executive Officer at Citibank Mexico SA, an Independent Director at Forest Laboratories, Inc., an Independent Non-Executive Director at Computershare Ltd., and a Director at SCB, Inc. He was also a Director, SVP-Finance & Administration at Sanford C. Bernstein & Co. LLC, the President, Chief Operating Officer & Director at AllianceBernstein Holding LP, and the Senior Human Resources Officer at Citicorp, Inc. Furthermore, Mr. Lieberman held the position of Head-Latin America Region at Citibank NA (New York), President & Chief Operating Officer at Alliance Capital Management Holding LP, and President at AllianceBernstein LP. He also served as the Chief Financial & Administrative Officer at FMR LLC and as a Trustee at The University of Connecticut Foundation, Inc. Mr. Lieberman obtained his undergraduate degree from the University of Connecticut in 1969. |
